格隆汇10月17日丨上海医药(02607.HK)宣布，董事会会议将于2025年10月30日（星期四）举行，藉以 （其中包括）批准本公司及其附属公司截至2025年9月30日止九个月的第三季度业绩及其发布，并考虑 派发中期股息（如有）。 ...

（股份代碼：02607） 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其 準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容 而產生或因依賴該等內容而引致的任何損失承擔任何責任。 中國上海，二零二五年十月十七日 於本公告日期，本公司的執行董事為楊秋華先生、沈波先生、李永忠先生及董明先生； 非執行董事為張文學先生；以及獨立非執行董事為顧朝陽先生、霍文遜先生、王忠先生 及萬鈞女士。 上海醫藥集團股份有限公司 Shanghai Pharmaceuticals Holding Co., Ltd.* （於中華人民共和國註冊成立的股份有限公司） 董事會會議通告 上海醫藥集團股份有限公司（「本公司」）董事會（「董事會」）謹此宣佈， 董事會會議將於二零二五年十月三十日（星期四）舉行，藉以（其中包括）批 准本公司及其附屬公司截至二零二五年九月三十日止九個月之第三季度業績及 其發佈，並考慮派發中期股息（如有）。 承董事會命 上海醫藥集團股份有限公司 楊秋華 董事長 * 僅供識別 ...

Group 1 - High Energy Environment reported a net profit of 646 million yuan for the first three quarters, a year-on-year increase of 15.18% [1] - Tianzhun Technology received approval from the China Securities Regulatory Commission for issuing convertible bonds to unspecified objects [1] - Energy Conservation Wind Power achieved a cumulative power generation of 9.349 billion kWh, a year-on-year increase of 1.72% [1][2] Group 2 - Sichuan Road and Bridge's total amount of projects won in the first three quarters reached 97.173 billion yuan, a year-on-year increase of 25.16% [3] - Shaanxi Energy's power generation in the third quarter decreased by 1% year-on-year, while its coal sales increased by 136.98% [3][4] Group 3 - Jintuo Co. announced that four shareholders plan to reduce their holdings by up to 2.95% of the company's shares [5] - Tailin Microelectronics expects a net profit increase of 118% year-on-year for the first three quarters, with revenue of approximately 766 million yuan [6] - Asia-Pacific Co. anticipates a net profit of 310 million to 335 million yuan for the first three quarters, a year-on-year increase of 97.38% to 113.30% [8] Group 4 - He Sheng New Materials expects a net profit increase of 60% to 80% for the first three quarters, with a projected profit of 137 million to 154 million yuan [9] - Spring Airlines reported a passenger turnover of 4.835 billion person-kilometers in September, a year-on-year increase of 22.87% [10][11] Group 5 - Mingxin Xuteng received a notification from a leading new energy vehicle company for a project worth approximately 650 million yuan [12] - Acolyte's subsidiary received a government subsidy of 47.13 million yuan for fixed asset investment [13] Group 6 - Fangsheng Pharmaceutical's subsidiary received approval for clinical trials of a new drug for treating advanced prostate cancer [14] - Aofu Technology plans to sell idle factory assets for a total price of 23.852 million yuan [16] Group 7 - Ganyue Expressway reported a service income of 313 million yuan in September [18] - Dong'an Power secured five new market agreements in the third quarter, with a total projected sales volume of approximately 1 million units [20] Group 8 - Zhongmin Energy achieved a cumulative power generation of 1.922 billion kWh, a year-on-year increase of 1.25% [21] - Pan-Asia Micro-Pore's application for issuing shares to specific objects has been accepted by the Shanghai Stock Exchange [23] Group 9 - Shenghui Integration reported an order balance of 2.214 billion yuan as of September 30, a year-on-year increase of 21.21% [24] - Jineng Technology's vice president resigned for personal reasons [25] Group 10 - Ruixin Microelectronics expects a net profit increase of 116% to 127% for the first three quarters, with a projected profit of 760 million to 800 million yuan [33] - Shanghai Pharmaceuticals received FDA approval for a new drug application for doxycycline capsules [34] Group 11 - Ruima Precision's subsidiary received a project notification for air suspension systems from a domestic automaker, with a total sales forecast of approximately 265 million yuan [36] - Galaxy Magnetics anticipates some impact on its export business due to the Ministry of Commerce's announcement on export controls for certain rare earth items [37] Group 12 - Ba Tian Co. expects a net profit increase of 230.79% to 260.15% for the first three quarters, with a projected profit of 676 million to 736 million yuan [43] - Donglai Technology plans to reduce its repurchased shares by up to 1% of the total share capital [45] Group 13 - Guangkang Biochemical announced that shareholders plan to reduce their holdings by up to 2.68% of the company's shares [46] - Nanwang Energy reported a net profit increase of 37.13% for the first three quarters, with a total revenue of 5.32 billion yuan [48] Group 14 - Yahua Group expects a net profit increase of 106.97% to 132.84% for the first three quarters, with a projected profit of 320 million to 360 million yuan [49] - Hualitai's annual production project for 20,000 tons of benzidine has been successfully completed and is now in full production [51]

Core Viewpoint - Shanghai Pharmaceuticals' subsidiary, Changzhou Pharmaceutical Factory, received approval from the U.S. FDA for its Abbreviated New Drug Application (ANDA) for doxycycline capsules, marking a significant step in expanding its overseas market presence [1] Summary by Categories Company Developments - The company has invested approximately 10.83 million yuan in the research and development of doxycycline capsules as of the announcement date [1] - The approval of the ANDA is expected to provide valuable experience for the company in navigating international markets [1] Market Implications - The approval is seen as a positive development for the company, enhancing its ability to expand into overseas markets [1]

Core Viewpoint - Shanghai Pharmaceuticals has received approval from the Malaysian National Pharmaceutical Regulatory Agency (NPRA) for the marketing of its rivaroxaban tablets, indicating a significant milestone for the company in expanding its product offerings in international markets [2] Company Summary - Shanghai Pharmaceuticals' subsidiary, Changzhou Pharmaceutical Factory Co., Ltd., is responsible for the production of the rivaroxaban tablets that have now been registered for sale in Malaysia [2] Industry Summary - The approval of rivaroxaban tablets in Malaysia reflects the growing demand for anticoagulant medications in the Southeast Asian market, highlighting potential growth opportunities for pharmaceutical companies operating in this region [2]

Core Viewpoint - Shanghai Pharmaceuticals announced the approval of its abbreviated new drug application (ANDA) for doxycycline capsules by the U.S. Food and Drug Administration (FDA) [2] Company Summary - Shanghai Pharmaceuticals' subsidiary, Changzhou Pharmaceutical Factory, received notification from the FDA regarding the approval of its ANDA for doxycycline capsules [2]

Core Viewpoint - Shanghai Pharmaceuticals has received FDA approval for its abbreviated new drug application (ANDA) for doxycycline capsules, indicating a significant milestone for the company in the U.S. market [1] Company Summary - Shanghai Pharmaceuticals' subsidiary, Changzhou Pharmaceutical Factory, is the entity that received the FDA notification regarding the approval [1] - The approved doxycycline capsules contain two types of microcapsules: 30mg immediate-release and 10mg delayed-release, targeting inflammatory lesions in adult patients with rosacea [1]

Core Viewpoint - Shanghai Pharmaceuticals (02607.HK) announced a significant equity adjustment involving its actual controller, the Shanghai State-owned Assets Supervision and Administration Commission, which will transfer all shares of Shanghai Industrial (Group) Co., Ltd. to Jinzhong International Holdings Limited [1] Group 1 - Following the equity adjustment, the shareholding of Shanghai Industrial (Group) Co., Ltd. in the company will increase from 25.303% to 38.487% [1] - The equity adjustment will not result in a change of the company's controlling shareholder or actual controller, which will remain the Shanghai State-owned Assets Supervision and Administration Commission [1]

Core Viewpoint - Shanghai Pharmaceuticals has received FDA approval for its abbreviated new drug application (ANDA) for Doxycycline Capsules, marking a significant milestone for the company in the U.S. market [1] Group 1: Company Announcement - Shanghai Pharmaceuticals' subsidiary, Changzhou Pharmaceutical Factory, has been notified by the U.S. FDA regarding the approval of its ANDA for Doxycycline Capsules [1] - The Doxycycline Capsules (40mg) contain two types of micro-pellets: 30mg immediate-release and 10mg delayed-release, primarily used for treating inflammatory lesions of rosacea in adult patients [1] - The original drug was developed by Galderma Laboratories LP and was launched in the U.S. in 2006 [1] Group 2: Financial Investment - As of the date of the announcement, the company has invested approximately RMB 10.83 million in the research and development of this drug [1] - The ANDA application for the drug was submitted to the U.S. FDA in September 2024 and has recently been approved for marketing [1]

Core Viewpoint - Shanghai Pharmaceuticals has received approval from the U.S. FDA for its abbreviated new drug application (ANDA) for Doxycycline Capsules, indicating a significant milestone for the company in the U.S. market [1] Group 1: Company Announcement - Shanghai Pharmaceuticals' subsidiary, Changzhou Pharmaceutical Factory, has successfully obtained FDA approval for Doxycycline Capsules [1] - The drug is primarily used for treating inflammatory lesions of rosacea in adult patients [1] - The original drug was developed by Galderma Laboratories LP and was launched in the U.S. in 2006 [1] Group 2: Financial Investment - The company has invested approximately RMB 10.83 million in research and development for this drug as of the announcement date [1] - The Doxycycline Capsules consist of two types of microcapsules: 30mg immediate-release and 10mg delayed-release [1] Group 3: Regulatory Milestone - The ANDA application for Doxycycline was submitted to the FDA in September 2024 and has now been approved [1]